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Editorial on the Research Topic
Antidepressant Prescriptions in Children and Adolescents
The use of antidepressants in children and adolescents has a troubled history, for almost all
principles of good evidence-based medicine were violated or compromised. It is a history
characterized by systematically biased research, financial conflicts of interest, and professional
recklessness (1–3). In 2004, the Lancet Editors (4), in an article titled “Depressing research”
bluntly stated that “The story of research into selective serotonin reuptake inhibitor (SSRI) use
in childhood depression is one of confusion, manipulation, and institutional failure” (p. 1335).
It is now well-established that most pediatric antidepressant trials were industry-sponsored and
had serious methodological limitations; many trials remained unpublished due to unfavorable
results, and those published were mostly ghost-written, selectively reported efficacy outcomes and
misrepresented the true rate of treatment-emergent suicidal events (5–9). Drug regulators issued a
suicidality warning for pediatric antidepressant use in 2003 (MHRA) and 2004 (FDA) and advised
to use fluoxetine only. By consequence, some authors argued that SSRI should be reserved as a
second-line option for youth with severe and resistant forms of depression (10).
However, in most countries antidepressant use has considerably increased in children and
adolescent over the last 10–15 years (11–13), despite suicidality warnings, the serious limitations
of the evidence-base (14), and ongoing controversies surrounding risks and benefits (15) as well
as the placebo response (16). The aim of this special topic was thus to provide a collection
of articles broadly focused on two main issues; first, on the current scientific evidence for the
efficacy and safety of antidepressants, with a special emphasis on suicidality and related regulatory
warnings, and, second, on recent trends in prescription rates and patterns of utilization, including
antidepressant overuse, and the increasingly medicalized approach to mental health.
Safer and Zito reviewed the efficacy of new-generation antidepressants for pediatric depression.
They found no meaningful benefits in children and only marginal benefits in adolescents based
on placebo-controlled short-term trials. Moreover, they considered the evidence for maintenance
treatment based on discontinuation (placebo-substitution) trials problematic and inconclusive due
to high dropout rates, potential withdrawal syndromes that mimic relapse, and relapse rates not
dissimilar from the natural course of the disorder.
Boaden et al. conducted a meta-review on the efficacy, tolerability, and suicidality-risk of
antidepressants for the treatment of various pediatric disorders. The meta-review found that just
a few antidepressants were effective and well-tolerated. For instance, only fluoxetine was more
effective than placebo in major depression, and only fluvoxamine and paroxetine were effective
in anxiety disorders. Venlafaxine (in major depression) and paroxetine (in anxiety disorders)
were associated with significantly increased risk of suicidality. However, of the nine meta-analyses
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included, only one met criteria of high quality; five were rated
moderate quality, one was of low quality and two of critically low
quality. The authors further state that the quality of the available
evidence is inadequate due to short trial duration, selective
reporting and publication bias, and they emphasize the paucity
of data on suicidal ideation and behavior in antidepressant trials.
The issue of increased risk of suicidality with antidepressants
was specifically addressed in two articles. In the first, Spielmans
et al. review the scientific evidence and conclude that the FDA
black-box suicidality warning was justified and firmly rooted in
solid data from placebo-controlled antidepressant trials. They
further detail that prominent claims suggesting that the FDA
warning has led to decreasing prescription rates and thus
increasing suicide rates were based on methodologically weak
and potentially misleading ecological studies.
In the second, Whitely et al. describe how prominent
psychiatrists and influential mental health organizations
challenged the black-box suicidality warning for adolescents and
young adults. The authors argue that various ecological studies
were cited misleadingly as evidence that increased antidepressant
use reduces youth suicide risk. Contrary to these claims, they
further show that, in Australia, both antidepressant use and
suicide rates increased substantially from 2008 to 2018.
Another serious safety issue was addressed by Kapra et al..
In their mini review they discuss the evidence for and against
a potential effect of antidepressant use during pregnancy on
autism spectrum disorders in the offspring. The authors found
evidence for an association between prenatal SSRI exposure and
an increased risk of autism spectrum disorders based on several
observational studies, but caution that causality has not been
demonstrated yet due to confounding by indication. The authors
conclude that there is a need for more research on this serious
safety issue, as accumulating data from animal studies suggest
that SSRI exposure may alter normal brain development.
Trends of increasing antidepressant use in young people
were addressed in two articles. In the first, Zito et al. analyzed
administrative claims of Medicaid-insured youth aged <20 years
from 1987 to 2014. During this 28-year period, antidepressant
use grew 14-fold. They further show that in 2014, antidepressants
were prescribed six times more often for youth in foster care
than for their income-eligible Medicaid-counterparts. Off-label
prescribing was also very common: a quarter of antidepressant-
medicated youth were diagnosed with a behavioral disorder.
In the second, Cosgrove et al. state that antidepressant use
in children and adolescents rose substantially over the last 15
years in part due to commercially driven off-label prescriptions,
despite ongoing controversy over their effectiveness and safety.
From the perspective of institutional corruption, they discuss
two drivers of overuse resulting from an increasingly medicalised
approach to mental health. The first is the empirically
unsupported demand for depression screenings in youth and
the second the emphasis on scaling up diagnosis and treatment
of mental disorders as part of a renewed Global Mental
Health Movement.
Last but not least, Locher et al. make an interesting case
for open-label placebos in the treatment of chronic pain
conditions in children and adolescents as an alternative to
long-term antidepressant use. The authors acknowledge that
this approach still lacks empirical evidence, but also stress that
open-label placebos constitute a promising avenue for future
research as they may help to mitigate the serious adverse effects
of antidepressants.
In conclusion, the articles in this special topic demonstrate
that pediatric antidepressant use is still controversial. Although
antidepressant use in children and adolescents has increased
substantially over the last 10–15 years, convincing evidence
that the benefits outweigh the risks is lacking and treatment-
emergent suicidality remains a major concern. Overuse and off-
label prescribing are pressing issues, and there certainly is a need
for safer and more effective treatments, both pharmacological
and psychological (17). It is hoped that this article collection will
spur innovative research and critical discussion.
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